Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00664664 · ClinicalTrials.gov registry record · Phase 2
Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia
A Phase 2 study, sponsored by Arena Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 744
- Enrollment target
NCT00664664 is a Phase 2 study that has completed, run by Arena Pharmaceuticals. The registered enrollment target is 744 participants.
The verdict
NCT00664664, a Phase 2 study, has completed, sponsored by Arena Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 744 participants
- Enrollment target
Study Summary
This study is designed to compare 2 doses of APD125 (20 mg and 40 mg) with placebo in otherwise healthy adults with primary insomnia primarily with complaints of maintaining sleep. Participants will be required to maintain a daily sleep dairy for up to 3 weeks while on study.
Interventions
- DRUG Placebo
- DRUG APD125
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 744 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00664664
The ClinicalTrials.gov registry entry for NCT00664664 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 744 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arena Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00664664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00664664 about?
NCT00664664 is a clinical study titled "Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia". This study is designed to compare 2 doses of APD125 (20 mg and 40 mg) with placebo in otherwise healthy adults with primary insomnia primarily with complaints of maintaining sleep. Participants will be required to maintain a daily sleep dairy for up to 3 weeks while on study.
What is the current status of trial NCT00664664?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 744 participants. The study started on 2008-04. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00664664?
The interventions under investigation include: Placebo (DRUG), APD125 (DRUG).
Who is sponsoring clinical trial NCT00664664?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.